The Pulse of New York Tech
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. Founded in 2017, Synklino is backed by investors that include EIR Ventures and Vaekstfonden and is headquartered in Lyngby.
WRITE FOR US
NYC TECH EVENTS
NYC TECH NEWS
Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.